P08069

※ Protein Information

Tag	Content
UniProt Accession	IGF1R_HUMAN; P08069;
Entrez ID	3480
GenBank Protein ID	NM_000875.4; NM_001291858.1;
GenBank Nucleotide ID	NP_000866.1; NP_001278787.1;
Protein Name	Insulin-like growth factor 1 receptor (EC 2.7.10.1) (Insulin-like growth factor I receptor) (IGF-I receptor) (CD antigen CD221) [Cleaved into: Insulin-like growth factor 1 receptor alpha chain; Insulin-like growth factor 1 receptor beta chain]
Gene Name	IGF1R
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), S(view all) Functional Description Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.;When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
Sequence (Fasta)	MKSGSGGGSP TSLWGLLFLS AALSLWPTSG EICGPGIDIR NDYQQLKRLE NCTVIEGYLH 60 ILLISKAEDY RSYRFPKLTV ITEYLLLFRV AGLESLGDLF PNLTVIRGWK LFYNYALVIF 120 EMTNLKDIGL YNLRNITRGA IRIEKNADLC YLSTVDWSLI LDAVSNNYIV GNKPPKECGD 180 LCPGTMEEKP MCEKTTINNE YNYRCWTTNR CQKMCPSTCG KRACTENNEC CHPECLGSCS 240 APDNDTACVA CRHYYYAGVC VPACPPNTYR FEGWRCVDRD FCANILSAES SDSEGFVIHD 300 GECMQECPSG FIRNGSQSMY CIPCEGPCPK VCEEEKKTKT IDSVTSAQML QGCTIFKGNL 360 LINIRRGNNI ASELENFMGL IEVVTGYVKI RHSHALVSLS FLKNLRLILG EEQLEGNYSF 420 YVLDNQNLQQ LWDWDHRNLT IKAGKMYFAF NPKLCVSEIY RMEEVTGTKG RQSKGDINTR 480 NNGERASCES DVLHFTSTTT SKNRIIITWH RYRPPDYRDL ISFTVYYKEA PFKNVTEYDG 540 QDACGSNSWN MVDVDLPPNK DVEPGILLHG LKPWTQYAVY VKAVTLTMVE NDHIRGAKSE 600 ILYIRTNASV PSIPLDVLSA SNSSSQLIVK WNPPSLPNGN LSYYIVRWQR QPQDGYLYRH 660 NYCSKDKIPI RKYADGTIDI EEVTENPKTE VCGGEKGPCC ACPKTEAEKQ AEKEEAEYRK 720 VFENFLHNSI FVPRPERKRR DVMQVANTTM SSRSRNTTAA DTYNITDPEE LETEYPFFES 780 RVDNKERTVI SNLRPFTLYR IDIHSCNHEA EKLGCSASNF VFARTMPAEG ADDIPGPVTW 840 EPRPENSIFL KWPEPENPNG LILMYEIKYG SQVEDQRECV SRQEYRKYGG AKLNRLNPGN 900 YTARIQATSL SGNGSWTDPV FFYVQAKTGY ENFIHLIIAL PVAVLLIVGG LVIMLYVFHR 960 KRNNSRLGNG VLYASVNPEY FSAADVYVPD EWEVAREKIT MSRELGQGSF GMVYEGVAKG 1020 VVKDEPETRV AIKTVNEAAS MRERIEFLNE ASVMKEFNCH HVVRLLGVVS QGQPTLVIME 1080 LMTRGDLKSY LRSLRPEMEN NPVLAPPSLS KMIQMAGEIA DGMAYLNANK FVHRDLAARN 1140 CMVAEDFTVK IGDFGMTRDI YETDYYRKGG KGLLPVRWMS PESLKDGVFT TYSDVWSFGV 1200 VLWEIATLAE QPYQGLSNEQ VLRFVMEGGL LDKPDNCPDM LFELMRMCWQ YNPKMRPSFL 1260 EIISSIKEEM EPGFREVSFY YSEENKLPEP EELDLEPENM ESVPLDPSAS SSSLPLPDRH 1320 SGHKAENGPG PGVLVLRASF DERQPYAHMN GGRKNERALP LPQSSTC 1368 Fasta Sequence >P08069\|IGF1R\|Homo sapiens (Human) MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLHILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIFEMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGDLCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCSAPDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHDGECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNLLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSFYVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTRNNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDGQDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSEILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRHNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRKVFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFESRVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTWEPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGNYTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHRKRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIMELMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGVVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRHSGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC

※ PTM-Disease Association

Num	PTM	Disease	Cell Type	Type	PTM Site	PMID
1	Glycosylation	Prostate cancer/carcinoma/adenocarcinoma		P		23724116
1	[Reference]: we have established that the glycosylation of IGF-1R is necessary for the full activation of the receptor in response to androgen treatment and that perturbing this process can break the feedback loop between AR and IGF-1R activation in prostate cells.
2	Phosphorylation	Barrett's neoplasia		U		14608530
2	[Reference]: Our data indicate that expression levels of IGF1-R, c-Src, and Bcl-X(L) proteins are coordinately elevated in Barrett's-associated neoplasia.?
3	Tyrosine Phosphorylation	Neuroblastoma		U	Y1161	24349301
3	[Reference]: Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.
4	Tyrosine Phosphorylation	Breast cancer/tumor/carcinoma	tumor tissue	U	Y1165	23663564
4	[Reference]: Expression of phosphorylated IGF-1R was greater in BCSCs than in non-BCSCs from xenografts of human breast cancer
5	Tyrosine Phosphorylation	Breast cancer/tumor/carcinoma	tumor tissue	U	Y1166	23663564
5	[Reference]: Expression of phosphorylated IGF-1R was greater in BCSCs than in non-BCSCs from xenografts of human breast cancer

※ Disease Cross-ref Annotation

Database	Annotation
CTD (Curated) (count: 17) (view all)	MESH:D018268 ; Adrenocortical Carcinoma MESH:D000544 ; Alzheimer Disease MESH:D001171 ; Arthritis, Juvenile MESH:D001943 ; Breast Neoplasms MESH:D006528 ; Carcinoma, Hepatocellular MESH:D002471 ; Cell Transformation, Neoplastic MESH:D016889 ; Endometrial Neoplasms MESH:D005317 ; Fetal Growth Retardation MESH:D006130 ; Growth Disorders MESH:D065630 ; Hernias, Diaphragmatic, Congenital MESH:C564816 ; Insulin-Like Growth Factor I, Resistance To MESH:D020961 ; Lewy Body Disease MESH:D008171 ; Lung Diseases MESH:D010300 ; Parkinson Disease MESH:D010523 ; Peripheral Nervous System Diseases MESH:D012131 ; Respiratory Insufficiency MESH:D012878 ; Skin Neoplasms
DisGeNet (Curated) (count: 64) (view all)	C0002395; Alzheimer's Disease C0003467; Anxiety C0007621; Neoplastic Cell Transformation C0014170; Endometrial Neoplasms C0015934; Fetal Growth Retardation C0018273; Growth Disorders C0021296; Infant, Small for Gestational Age C0023012; Language Delay C0024115; Lung diseases C0025362; Mental Retardation C0030567; Parkinson Disease C0031117; Peripheral Neuropathy C0035229; Respiratory Insufficiency C0037286; Skin Neoplasms C0041667; Underweight C0085631; Agitation C0206686; Adrenocortical carcinoma C0233715; Speech impairment C0235833; Congenital diaphragmatic hernia C0241210; Speech Delay C0265610; Congenital clinodactyly C0266617; Congenital anomaly of face C0349588; Short stature C0423903; Low intelligence C0424503; Dysmorphic facies C0424688; Small head C0426429; Broad nasal tip C0454644; Delayed speech and language development C0541764; Delayed bone age C0578038; Thin lips C0752347; Lewy Body Disease C0917816; Mental deficiency C1142533; Smooth philtrum C1262477; Weight decreased C1385263; facial deformity C1386048; Intrauterine retardation C1458155; Mammary Neoplasms C1827524; Wide spaced nipples C1836189; Radially deviated fingers C1839764; Broad flat nasal bridge C1843108; Short hands C1843367; Poor school performance C1844806; Weight less than 3rd percentile C1849157; Insulin-Like Growth Factor I, Resistance To C1849367; Nasal bridge wide C1853246; Everted lower lip vermilion C1854301; Motor delay C1865014; Long philtrum C1865017; Thin upper lip vermilion C1866234; Protruding lower lip C2051831; Pectus excavatum C2239176; Liver carcinoma C2676198; Increased serum IGF1 C2752013; Prenatal onset C3495559; Juvenile arthritis C3714756; Intellectual Disability C4020874; No development of motor milestones C4020876; Dull intelligence C4020884; Anxiety disease C4020899; Autosomal recessive predisposition C4025763; Abnormality of the rib cage C4072832; Distortion of face C4072833; Funny looking face C4280304; Curvature of digit
HGMD (count: 14) (view all)	CP070609; Overgrowth; Complex rearrangements CG083431; Growth retardation; Gross deletions CN025094; Overgrowth; Gross insertions CI091805; Short stature; Small insertions CM081312; Increased longevity, association with; Missense/nonsense CM035075; Growth retardation; Missense/nonsense CM035076; Growth retardation; Missense/nonsense CM035077; Growth retardation; Missense/nonsense CM081311; Increased longevity, association with; Missense/nonsense CM081310; Increased longevity, association with; Missense/nonsense CM071804; Growth retardation; Missense/nonsense CM052887; Growth retardation; Missense/nonsense CM031698; Increased longevity, association with ?; Missense/nonsense CM061798; Growth retardation; Missense/nonsense
GWASdb (count: 74) (view all)	rs2871865; Height; Null rs10902606; Type 2 diabetes; type 2 diabetes mellitus rs11854132; Serum metabolites; Null rs4966014; Urate levels; gout rs11858316; Urate levels; gout rs7174918; Urate levels; gout rs8032477; Urate levels; gout rs3803476; Alcohol dependence; alcohol dependence rs3803476; Response to taxane treatment (placlitaxel); lung cancer rs3803476; Urate levels; gout rs2018860; Urate levels; gout rs11634241; Urate levels; gout rs8038015; Urate levels; gout rs11857366; Acute lymphoblastic leukemia (childhood); acute lymphocytic leukemia\|acute leukemia rs11857366; Response to taxane treatment (placlitaxel); lung cancer rs11857366; Urate levels; gout rs4966017; Alcohol dependence; alcohol dependence rs4966017; Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption); hypertension rs4966017; Alcoholism; alcohol dependence rs932071; Urate levels; gout rs4616271; Urate levels; gout rs4965430; Urate levels; gout rs6598541; Urate levels; gout rs875686; Urate levels; gout rs11633717; Urate levels; gout rs7166287; Urate levels; gout rs4966019; Urate levels; gout rs11633294; Urate levels; gout rs907808; Urate levels; gout rs2175800; Lung function (forced vital capacity); lung disease rs2175800; Lung function (forced expiratory volume in 1 second); lung disease rs1567811; Urate levels; gout rs3743263; Urate levels; gout rs3743264; Urate levels; gout rs1007212; Urate levels; gout rs2871974; Urate levels; gout rs8037467; Urate levels; gout rs4966020; Urate levels; gout rs4966021; Urate levels; gout rs4966022; Urate levels; gout rs7176092; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs12908437; Response to taxane treatment (placlitaxel); lung cancer rs12908437; Urate levels; gout rs2137683; Response to taxane treatment (placlitaxel); lung cancer rs2137683; Urate levels; gout rs11632952; Urate levels; gout rs7166999; Response to taxane treatment (placlitaxel); lung cancer rs7166999; Urate levels; gout rs6598542; Response to taxane treatment (placlitaxel); lung cancer rs6598542; Urate levels; gout rs6598543; Urate levels; gout rs12898337; Response to taxane treatment (placlitaxel); lung cancer rs12898337; Urate levels; gout rs12898502; Response to taxane treatment (placlitaxel); lung cancer rs12898502; Urate levels; gout rs4966024; Response to taxane treatment (placlitaxel); lung cancer rs4966024; Urate levels; gout rs8041224; Urate levels; gout rs10794486; Hypertension (early onset hypertension); hypertension rs2048640; Type 2 diabetes; type 2 diabetes mellitus rs2048639; Type 2 diabetes; type 2 diabetes mellitus rs7175052; Hypertension (early onset hypertension); hypertension rs8031382; Weight loss (gastric bypass surgery); obesity rs12439557; Weight loss (gastric bypass surgery); obesity rs4267291; Lipid levels; lipid metabolism disorder\|cardiovascular system disease\|obesity rs7182064; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs2684777; Iron levels; iron metabolism disease rs2715442; Non-alcoholic fatty liver disease histology (other); fatty liver disease rs1357112; Urinary metabolites; kidney disease rs3743258; Suicide attempts in bipolar disorder; bipolar disorder rs8038056; Hemoglobin concentration; hemoglobinopathy rs2684796; Hemoglobin concentration; hemoglobinopathy rs7173377; Coronary heart disease; coronary artery disease rs17847195; Coronary heart disease; coronary artery disease

※ PTM Sites

PTM	Modification Sites
Phosphorylation (count: 42) (view all)	1014 QGSFGMVYEGVAKGV dbPAF 11 GSGGGSPTSLWGLLF dbPAF 113 IRGWKLFYNYALVIF dbPAF 115 GWKLFYNYALVIFEM dbPAF 1161 FGMTRDIYETDYYRK dbPAF 1163 MTRDIYETDYYRKGG dbPAF 1165 RDIYETDYYRKGGKG dbPAF 1166 DIYETDYYRKGGKGL dbPAF 1193 DGVFTTYSDVWSFGV dbPAF 12 SGGGSPTSLWGLLFL dbPAF 123 ALVIFEMTNLKDIGL dbPAF 1278 EPGFREVSFYYSEEN dbPAF 1280 GFREVSFYYSEENKL dbPAF 1281 FREVSFYYSEENKLP dbPAF 1308 ESVPLDPSASSSSLP dbPAF 131 NLKDIGLYNLRNITR dbPAF 1310 VPLDPSASSSSLPLP dbPAF 1311 PLDPSASSSSLPLPD dbPAF 1312 LDPSASSSSLPLPDR dbPAF 1313 DPSASSSSLPLPDRH dbPAF 1321 LPLPDRHSGHKAENG dbPAF 1339 GVLVLRASFDERQPY dbPAF 1346 SFDERQPYAHMNGGR dbPAF 1364 RALPLPQSSTC** dbPAF 1365 ALPLPQSSTC* dbPAF 1366 LPLPQSSTC** dbPAF 28 AALSLWPTSGEICGP dbPAF 29 ALSLWPTSGEICGPG dbPAF 3 *MKSGSGGGSP dbPAF 345 TKTIDSVTSAQMLQG dbPAF 346 KTIDSVTSAQMLQGC dbPAF 354 AQMLQGCTIFKGNLL dbPAF 468 RMEEVTGTKGRQSKG dbPAF 5 *MKSGSGGGSPTS dbPAF 577 GLKPWTQYAVYVKAV dbPAF 580 PWTQYAVYVKAVTLT dbPAF 623 DVLSASNSSSQLIVK dbPAF 624 VLSASNSSSQLIVKW dbPAF 9 KSGSGGGSPTSLWGL dbPAF 973 RLGNGVLYASVNPEY dbPAF 980 YASVNPEYFSAADVY dbPAF 982 SVNPEYFSAADVYVP dbPAF
Ubiquitination (count: 11) (view all)	1033 PETRVAIKTVNEAAS PLMD 1055 LNEASVMKEFNCHHV PLMD 1088 LMTRGDLKSYLRSLR PLMD 1130 MAYLNANKFVHRDLA PLMD 403 LVSLSFLKNLRLILG PLMD 453 MYFAFNPKLCVSEIY PLMD 502 FTSTTTSKNRIIITW PLMD 672 KDKIPIRKYADGTID PLMD 688 EEVTENPKTEVCGGE PLMD 720 KEEAEYRKVFENFLH PLMD 812 SCNHEAEKLGCSASN PLMD
Sumoylation (count: 3)	1055 LNEASVMKEFNCHHV PLMD 1130 MAYLNANKFVHRDLA PLMD 1150 VAEDFTVKIGDFGMT PLMD
Methylation (count: 1)	1354 AHMNGGRKNERALPL PLMD

※ Protein-Protein Interaction

Network

Interaction

Source

C9JAF2	P08069	HPRD
O00459	P08069	HPRD; IntAct
O14508	P08069	HPRD
O14543	P08069	HPRD
O14654	P08069	HPRD
O14908	P08069	HPRD
O15524	P08069	HPRD
O15552	P08069	IntAct
O60674	P08069	HPRD
P01308	P08069	HPRD
P02458	P08069	BioGRID
P03372	P08069	HPRD
P04746	P08069	IntAct
P04899	P08069	HPRD
P05019	P08069	HPRD; DIP
P05556	P08069	HPRD
P06213	P08069	HPRD
P08069	P08069	HPRD; DIP; IntAct; MINT
P08069	P0CG48	HPRD
P08069	P12931	HPRD
P08069	P17936	HPRD
P08069	P18031	HPRD; MINT
P08069	P20936	HPRD
P08069	P22223	IntAct
P08069	P22681	HPRD
P08069	P23458	HPRD
P08069	P27986	HPRD; DIP
P08069	P29353	DIP; IntAct
P08069	P31946	HPRD; IntAct
P08069	P35568	HPRD; IntAct
P08069	P40763	HPRD
P08069	P41240	HPRD
P08069	P46108	HPRD;IntAct
P08069	P46109	HPRD
P08069	P46934	HPRD
P08069	P61981	HPRD; IntAct; MINT
P08069	P62258	HPRD; MINT
P08069	P62913	IntAct
P08069	P63096	HPRD
P08069	P63104	HPRD
P08069	P63244	HPRD
P08069	Q00987	HPRD; IntAct
P08069	Q03135	HPRD
P08069	Q05655	HPRD
P08069	Q06124	HPRD
P08069	Q13322	HPRD; MINT
P08069	Q14449	IntAct
P08069	Q14620	DIP
P08069	Q15075	HPRD
P08069	Q15139	HPRD
P08069	Q6PIS1	IntAct
P08069	Q7Z3Y8	HPRD
P08069	Q8TEW6	HPRD
P08069	Q92569	HPRD
P08069	Q99683	HPRD
P08069	Q9H4M9	HPRD
P08069	Q9NZN5	HPRD; MINT
P08069	Q9P104	HPRD
P08069	Q9UEF7	HPRD
P08069	Q9UKW4	HPRD
P08069	Q9Y4H2	HPRD; MINT

PTMD Annotation Information

※ Protein Information

Functional Description

Fasta Sequence

※ PTM-Disease Association

※ Disease Cross-ref Annotation

※ PTM Sites

※ Protein-Protein Interaction